Analytical Data
-
Gene name
IGFBP-3
- Application
-
Alternative Names
BP53; IBP3; Growth Hormone-Dependent Binding Protein; Acid Stable Subunit Of The 140 K IGF Complex
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P17936
-
Expression Region
Gly135~Thr277
-
Protein Length
Partial
-
Molecular Weight
38kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) is a crucial regulator of the insulin-like growth factor (IGF) signaling pathway, playing an essential role in cellular growth, differentiation, and apoptosis. Elevated levels of IGFBP-3 have been associated with various physiological and pathological conditions, including cancer, metabolic disorders, and aging. Research on recombinant IGFBP-3 has gained prominence due to its potential therapeutic applications, particularly in cancer treatment, where it has been shown to inhibit tumor growth by modulating the availability of IGFs and inducing apoptosis in malignant cells. Additionally, IGFBP-3 exhibits anti-inflammatory properties, making it a candidate for addressing metabolic diseases and cardiovascular issues. The ability to produce IGFBP-3 as a recombinant protein allows for the exploration of its biological functions and mechanisms of action in a controlled manner, facilitating the development of IGFBP-3-based therapies. Recent studies have focused on optimizing the expression systems for recombinant IGFBP-3, enhancing its stability and bioactivity, and understanding its interactions with other molecular pathways. As the body of research on IGFBP-3 continues to expand, it underscores the importance of this protein as a key player in cellular regulation and its potential as a therapeutic target in various diseases.
